Prolactin-releasing activity of arginine vasotocin in vitro.
A significant elevation in both luteinizing hormone (LH) and prolactin release was observed in the culture medium of hemipituitaries from castrated estrogen-progesterone (EP) primed female rats incubated for 5 h with arginine vasotocin (AVT) and luteinizing hormone-releasing hormone (LRH) compared to corresponding halves incubated with LRH alone. However, AVT alone did not significantly alter the discharge of LH or prolactin from hemipituitaries of EP-treated rats in vitro. Arginine vasopressin, a natural analogue of AVT, inhibited prolactin release using this same model system. Normal male rat hemipituitaries incubated with AVT released significantly more LH and prolactin into the culture medium than did their corresponding halves. A log-dose response curve indicated that any dose from 100 ng to 10 mug AVT significantly promoted prolactin release. However, the terminal tripeptide of AVT, Pro-Arg-Gly(NH2), failed to modify the discharge of LH or prolactin into the culture medium.
D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology; D002369:Castration; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D010902:Pituitary Gland / Q000378:metabolism; D011374:Progesterone / Q000494:pharmacology; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D014668:Vasotocin / Q000494:pharmacology*
D004967:Estrogens; D009842:Oligopeptides; D001127:Arginine Vasopressin; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D014668:Vasotocin